Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 125 Summer Street BOSTON MA 02110 |
Tel: | 1-781-3569763 |
Website: | https://www.haemonetics.com |
IR: | See website |
Key People | ||
Christopher A. Simon President, Chief Executive Officer, Director | James C. D'arecca Executive Vice President, Chief Financial Officer | Roy Galvin President - Global Plasma and Blood Center |
Stewart W. Strong President - Global Hospital | Laurie A. Miller Chief Human Resource Officer, Senior Vice President | Anila Lingamneni Executive Vice President, Chief Technology Officer |
Michelle L. Basil Executive Vice President, General Counsel | Josep L. Llorens Executive Vice President - Global Manufacturing and Supply Chain |
Business Overview |
Haemonetics Corporation is a global healthcare company. The Company provides a suite of medical products and solutions for customers to help them improve patient care and reduce the cost of healthcare. Its technology addresses three medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. Its segments include Plasma, Blood Center, and Hospital. Its Plasma segment offers automated plasma collection systems, donor management software, and supporting software solutions that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to collect and separate blood components for transfusions. Its Hospital segment provides patient care and has four product lines: hemostasis management, vascular closure, cell salvage, and transfusion management. Its portfolio also includes fiber optic sensor technology in the interventional cardiology market. |
Financial Overview |
For the 39 weeks ended 30 December 2023, Haemonetics Corporation revenues increased 12% to $965.8M. Net income increased 13% to $97.2M. Revenues reflect Plasma segment increase from $136.6M to $426.9M, Hospital segment increase from $93.9M to $316.7M, Blood Center segment increase from $76.8M to $207.8M, United States segment increase from $224.1M to $724.2M, Europe segment increase from $39.1M to $115.1M, Asia segment increase from $25.5M to $80.7M. |
Employees: | 3,034 as of Apr 1, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $5,055M as of Dec 30, 2023 |
Annual revenue (TTM): | $1,270M as of Dec 30, 2023 |
EBITDA (TTM): | $334.93M as of Dec 30, 2023 |
Net annual income (TTM): | $126.57M as of Dec 30, 2023 |
Free cash flow (TTM): | $128.75M as of Dec 30, 2023 |
Net Debt Last Fiscal Year: | $676.61M as of Dec 30, 2023 |
Shares outstanding: | 50,786,117 as of Feb 6, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |